NCT05891171
Clinical Trial Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05891171
Title Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25)
Acronym ARC-25
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Arcus Biosciences, Inc.
Indications
urinary bladder cancer
esophageal cancer
gastroesophageal junction adenocarcinoma
head and neck squamous cell carcinoma
renal cell carcinoma
triple-receptor negative breast cancer
lung non-small cell carcinoma
stomach cancer
ovarian cancer
cervical cancer
Therapies
AB598 + Carboplatin + Pemetrexed Disodium + Zimberelimab
AB598
AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab
Age Groups: senior | adult
Covered Countries USA | AUS

Facility Status City State Zip Country Details
Research Site Phoenix Arizona 85054 United States Details
Research Site Jacksonville Florida 32224 United States Details
Research Site Lake City Florida 32024 United States Details
Research Site Hinsdale Illinois 60521 United States Details
Research Site Detroit Michigan 48201 United States Details
Research Site Rochester Minnesota 55905 United States Details
Research Site New Brunswick New Jersey 08901 United States Details
Research Site Canton Ohio 44718 United States Details
Research Site Cleveland Ohio 44106 United States Details
Research Site Irving Texas 75039 United States Details
Research Site Fairfax Virginia 22031 United States Details
Research Site Adelaide Australia Details
Research Site Tainan Taiwan Details
Research Site Taipei Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field